Identifying Preliminary Domains to Detect and Measure Rheumatoid Arthritis Flares: Report of the OMERACT 10 RA Flare Workshop

REFERENCES

1. 1.
   1. Sanderson T,
   2. Morris M,
   3. Calnan M,
   4. Richards P,
   5. Hewlett S

   . Patient perspective of measuring treatment efficacy: the rheumatoid arthritis patient priorities for pharmacologic interventions outcomes. Arthritis Care Res (Hoboken) 2010;62(5):647–56.

   OpenUrlPubMed
2. 2.↵
   1. Bingham CO 3rd.,
   2. Pohl C,
   3. Woodworth TG,
   4. Hewlett SE,
   5. May JE,
   6. Rahman MU,
   7. et al.

   Developing a standardized definition for disease “flare” in rheumatoid arthritis (OMERACT 9 Special Interest Group). J Rheumatol 2009;36:2335–41.

   OpenUrlAbstract/FREE Full Text
3. 3.↵
   1. van Vollenhoven RF,
   2. Boumpas D,
   3. Westhovens R,
   4. Brzosko M,
   5. Svensson K,
   6. Bjorneboe O,
   7. et al.

   Response, remission, and flare during early treatment of rheumatoid arthritis with infliximab: The REMARK Study [abstract]. Ann Rheum Dis 2010;69 Suppl3:535.

   OpenUrl
4. 4.↵
   1. Den Broeder AA,
   2. Creemers MC,
   3. van Gestel AM,
   4. van Riel PL

   . Dose titration using the Disease Activity Score (DAS28) in rheumatoid arthritis patients treated with anti-TNF-alpha. Rheumatology 2002;41:638–42.

   OpenUrlAbstract/FREE Full Text
5. 5.↵
   1. van den Bemt BJ,
   2. den Broeder AA,
   3. Snijders GF,
   4. Hekster YA,
   5. van Riel PL,
   6. Benraad B,
   7. et al.

   Sustained effect after lowering high-dose infliximab in patients with rheumatoid arthritis: a prospective dose titration study. Ann Rheum Dis 2008;67:1697–701.

   OpenUrlAbstract/FREE Full Text
6. 6.↵
   1. Strand V,
   2. Crawford B

   . Improvement in health-related quality of life in patients with systemic lupus erythematosus following sustained reductions in anti-dsDNA antibodies. Expert Rev Pharmacoeconomics Outcomes Res 2005;5:317–26.

   OpenUrlCrossRef
7. 7.↵
   1. Bingham CO,
   2. Pohl C,
   3. Alten R,
   4. Christensen C,
   5. Choy EH,
   6. Hewlett SE,
   7. et al.

   “Flare” and disease worsening in rheumatoid arthritis: time for a definition. Int J Adv Rheumatol 2009;7:85–91.

   OpenUrl
8. 8.↵
   1. Alten R,
   2. Pohl C,
   3. Choy EH,
   4. Christensen R,
   5. Furst DE,
   6. Hewlett S,
   7. et al.

   Developing a construct to evaluate flares in rheumatoid arthritis: a conceptual report of the OMERACT RA Flare Definition Working Group. J Rheumatol 2011;38:1745–50.

   OpenUrlAbstract/FREE Full Text
9. 9.↵
   1. Woodworth T,
   2. Furst DE,
   3. Alten R,
   4. Bingham CO,
   5. Yocum D,
   6. Sloan V,
   7. et al.

   Standardizing assessment and reporting of adverse effects in rheumatology clinical trials II: the Rheumatology Common Toxicity Criteria v.2.0. J Rheumatol 2007;34:1401–14.

   OpenUrlAbstract/FREE Full Text
10. 10.↵
    1. Hewlett S,
    2. Sanderson T,
    3. May J,
    4. Alten R,
    5. Bingham CO,
    6. Cross M,
    7. et al.

    “I feel like a tractor has run over me”: Rheumatoid arthritis flare is more than a high joint count — an international patient perspective on flare where medical help is sought. Rheumatology 2011; [in press].
11. 11.↵
    1. Hewlett S,
    2. Sanderson T,
    3. May J,
    4. Bingham CO,
    5. March L,
    6. Alten R,
    7. et al.

    “Just shoot me”: RA patients experience flare as more than painful, swollen joints [abstract]. Rheumatology 2010;49 Suppl 1;141:285.

    OpenUrl
12. 12.↵
    1. Hewlett S,
    2. Sanderson T,
    3. May J,
    4. Bingham CO,
    5. March L,
    6. Alten R,
    7. et al.

    Patients’ words for scales to measure flare: “Sometimes it doesn’t fit into that neat little box” [abstract]. Rheumatology 2010;49 Suppl 1;143:289.

    OpenUrlAbstract/FREE Full Text
13. 13.↵
    1. Bykerk V

    . RA flares are common — BRASS [abstract]. Arthritis Rheum 2010;62 Suppl.
14. 14.↵
    1. Vander Cruyssen B,
    2. Van Looy S,
    3. Wyns B,
    4. Westhovens R,
    5. Durez P,
    6. Van den Bosch F,
    7. et al.

    DAS28 best reflects the physician’s clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: validation of the DAS28 score in patients under infliximab treatment. Arthritis Res Ther 2005;7:R1063–71.

    OpenUrlCrossRefPubMed
15. 15.↵
    1. Kirwan JR,
    2. Minnock P,
    3. Adebajo A,
    4. Bresnihan B,
    5. Choy E,
    6. de Wit M,
    7. et al.

    Patient perspective: fatigue as a recommended patient centered outcome measure in rheumatoid arthritis. J Rheumatol 2007;34:1174–7.

    OpenUrlAbstract/FREE Full Text
16. 16.↵
    1. Gossec L,
    2. Dougados M,
    3. Rincheval N,
    4. Balanescu A,
    5. Boumpas DT,
    6. Canadelo S,
    7. et al.

    Elaboration of the preliminary Rheumatoid Arthritis Impact of Disease (RAID) score: a EULAR initiative. Ann Rheum Dis 2009;68:1680–5.

    OpenUrlAbstract/FREE Full Text